Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Unicycive Therapeutics Q3 2026 Results: Net Loss of $7M, Loss Widens

Unicycive Therapeutics reported a net loss of $7.0 million for the quarter ended September 30, 2026, compared to $6.0 million in the prior year period. The company's cash position strengthened to $42.0 million, supported by $39.0 million in net proceeds from financing activities during the first nine months of 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-7.0-6.0
EPS (diluted, $ a share)$-0.25$-0.33

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: UNCY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Unicycive Therapeutics, Inc.: key numbers

Share price
$3.70Close, Nov 17
Market cap
$108M
Shares outstanding
29.18MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Unicycive Therapeutics, Inc.

All →
9:29 AM ET 8-K
Financial Results

Unicycive Therapeutics Financial Results

Unicycive Therapeutics reported third quarter 2026 financial results and provided a business update regarding its New Drug Application (NDA) for oxylanthanum carbonate (OLC). The FDA has accepted the NDA resubmission with a PDUFA target action date of March 25, 2027, following a previous Complete Response Letter related to manufacturing vendor deficiencies.

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients. With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”

Shalabh Gupta, M.D., Chief Executive Officer
7:46 AM ET 8-K
Leadership Change

Unicycive Therapeutics Leadership Change

Unicycive Therapeutics appointed Meredith S. Manning as an independent director to its board, effective October 1, 2026. Ms. Manning, who previously served as Chief Commercial Officer of Soleno Therapeutics, will also serve as Chairperson of the Nominating and Corporate Governance Committee. The company also announced the resubmission of its New Drug Application for Oxylanthanum Carbonate with a new manufacturing vendor.

Counterparty
Meredith S. Manning
4:31 PM ET 8-K
Court & Legal Update

Unicycive Therapeutics Court & Legal Update

A securities class action lawsuit has been filed against Unicycive Therapeutics and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges violations of federal securities laws regarding public statements about the company's New Drug Application for oxylanthanum carbonate. Unicycive stated it believes the claims are meritless and intends to vigorously defend the action.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.